Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition

Structure

Volumn 11, Issue 11, 2003, Pages 1329-1337

  Holton, Simon ^a   Merckx, Anais ^b   Burgess, Darren ^a,c   Doerig, Christian ^b   Noble, Martin ^a   Endicott, Jane ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 CYCLOHEXYLMETHOXY 2 (4' SULFAMOYLANILINO)PURINE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; INDIRUBIN 3' MONOXIME; INDIRUBIN 3' MONOXIME SULFONATE; INDIRUBIN 5 SULFONATE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTOZOAL PROTEIN; PURVALANOL B; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER THERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITOR COMPLEX; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN FOLDING; STRUCTURE ACTIVITY RELATION;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0242710962     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2003.09.020     Document Type: Article

References (38)

1. Barton G.J. Alscript. a tool to format multiple sequence alignments Protein Eng. 6:1993;37-40.
2. Bourne Y., Watson M.H., Hickey M.J., Holmes W., Rocque W., Reed S.I., Tainer J.A. Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell. 84:1996;863-874.
3. Brown N.R., Noble M.E., Endicott J.A., Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1:1999;438-443. a.
4. Brown N.R., Noble M.E.M., Lawrie A., Morris M., Tunnah P., Divita G., Johnson L.N., Endicott J.A. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 274:1999;8746-8756. b.
5. Brunger T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Panu N.S.et al. Crystallography and NMR system. Acta Crystallogr. D. 54:1998;905-921.
6. Chakrabarti D., Endicott J.A., Doerig C. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasit. 32:2002;1575-1585.
7. CCP4 The CCP4 (Collaborative Computational Project 4) suite. programs for protein crystallography Acta Crystallogr. D. 50:1994;760-763.
8. Cowtan K. Dm. an automated procedure for phase improvement by density modification Joint CCP. 4(and ESF-EACBM Newsletter on Protein Crystallography 31):1994;34-38.
9. Davies T.G., Bentley J., Arris C.E., Boyle F.T., Curtin N.J., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Hardcastle I.R.et al. Structure-based development and cellular pharmacology of a potent purine-based inhibitor of cyclin dependent kinases 1 and 2. Nat. Struct. Biol. 9:2002;745-749.
10. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature. 363:1993;595-602.
11. Doerig C., Chakrabarti D. The cell cycle in malaria parasites. a genomics perspective In Plasmodium Genomes and Their Molecular and Cellular Biology, A.P. Waters and C.J. Janse, eds. (Norfolk, UK: Horizon Press). in press:2003.
12. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B.et al. Protein kinases as targets for anticancer agents. from inhibitors to useful drugs Pharmacol. Ther. 93:2002;79-98.
13. Fischer P., Endicott J.A., Meijer L.M. Cyclin-dependent kinase inhibitors. Meijer L.M., Jezequel A., Roberge M. Cell Cycle Regulators as Therapeutic Targets. 2002;Editions Cloitre, Brittany. 235-268.pp.
14. Gardner M.J. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419:2002;498-511.
15. 6-substituted guanine derivatives. J. Med. Chem. 45:2002;3381-3393.
16. Graeser R., Wernli B., Franklin R.M., Kappes B. Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol. Biochem. Parasitol. 82:1996;37-49.
17. Gray N.S., Wodicka L., Thunnissen A.M.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., Leclerc S., Meijer L.et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
18. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily. kinase (catalytic) domain structure and classification FASEB J. 9:1995;576-596.
19. Henikoff S., Henikoff J.G. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA. 89:1992;10915-10919.
20. Hoessel R., Leclerc S., Endicott J.A., Noble M.E.M., Lawrie A.M., Tunnah P., Leost M., Damiens E., Marie D., Marko D.et al. Indirubin, the active constitutent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
21. Ikuta M., Kamata K., Fukasawa K., Honma T., Machida T., Hirai H., Suzuki-Takahashi I., Hayama T., Nishimura S. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 276:2001;27548-27554.
22. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 376:1995;313-320.
23. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved method for building models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
24. Knighton D.R., Zheng J.H., Ten-Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414.
25. Lawrie A.M., Noble M.E., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4:1997;796-801.
26. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M.et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276:2001;251-260.
27. Le Roch K., Sestier C., Dorin D., Waters N., Kappes B., Chakrabarti D., Meijer L., Doerig C. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. 275:2000;8952-8958.
28. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Meijor L., Guidet S., Tung H.Y.L. Progress in Cell Cycle Research. 1995;Plenum Press, New York. 1-13.pp.
29. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:1996;393-397.
30. Pattanaik P., Raman J., Balaram H. Perspectives in drug design against malaria. Curr. Top. Med. Chem. 2:2002;483-505.
31. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., Klaus B., Madwed J., Moriak M., Moss N.et al. Pyrazole urea-based inhibitors of p38 MAP kinase. from lead compound to clinical candidate J. Med. Chem. 45:2002;2994-3008.
32. Ridley R.G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature. 415:2002;686-693.
33. Russo A.A., Tong L., Lee J.O., Jeffrey P.D., Pavletich N.P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 395:1998;237-243.
34. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
35. Schulze-Gahmen U., Kim S.H. Structural basis for CDK6 activation by a virus-encoded cyclin. Nat. Struct. Biol. 9:2002;177-181.
36. Song H., Hanlon N., Brown N.R., Noble M.E., Johnson L.N., Barford D. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol. Cell. 7:2001;615-626.
37. Tarricone C., Dhavan R., Peng J., Areces L.B., Tsai L.H., Musacchio A. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell. 8:2001;657-669.
38. Thompson J.D., Higgins D.G., Gibson T.J. Clustal w. improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice Nucleic Acids Res. 22:1994;4673-4680.